Personalization of Large Foundation Models for Health Interventions

AI summary

Overview

Research area: Artificial intelligence in healthcare — specifically personalization of large foundation models (LFMs) for individual health interventions, bridging machine learning, causal inference, and personalized medicine (N-of-1 trials).

Technical level: Intermediate. The paper is conceptual rather than experimental, but it assumes familiarity with foundation models, causal inference vocabulary (counterfactuals, treatment effects, posterior updating), and clinical trial design.

Scope: The paper argues that LFMs alone cannot deliver causally valid personalized treatment recommendations, and proposes a hybrid framework in which population-trained LFMs generate ranked intervention hypotheses that are then validated through individual-level N-of-1 trials.

Authors and venue: Stefan Konigorski, Johannes E. Vedder, Babajide Alamu Owoyele, and İbrahim Özkan (Hasso Plattner Institute for Digital Engineering, University of Potsdam, Germany; Windreich Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York, USA). Posted as arXiv:2601.03482v1 [cs.AI], 07 Jan 2026, under CC BY 4.0.

What This Paper Is About

Large foundation models are increasingly used in healthcare for risk prediction, diagnosis, and treatment recommendation, but it remains unclear whether they can produce genuinely personalized recommendations for a single person. The paper identifies structural reasons why population-trained models cannot guarantee optimal individual treatment, and proposes combining LFMs with N-of-1 trials — repeated crossover self-experiments on one person — so that models generate hypotheses while individual experiments supply causal evidence.

Key Contributions

1. A formal statement of when personalized recommendations are guaranteed. The paper specifies three sufficient conditions ("Assumptions for Personalization"): (1) the treatment works for everyone all the time; (2) sufficient context information is available and the medication always works in that situation for everyone; or (3) sufficient context and patient information is available and the learned model is complex enough to have learned which intervention is optimal for every set of patient characteristics and every context. Outside these conditions, LFM recommendations are not guaranteed to be optimal and may be biased or harmful.

2. Identification of four structural tensions in AI-driven personalization — the generalizability paradox, the privacy-performance paradox, the scale-specificity paradox, and the automation-empathy paradox — each paired with a design requirement and a hybrid solution.

3. A hybrid LFM plus N-of-1 trial framework with three steps: foundation model as baseline population prior, N-of-1 trials for individual validation, and dynamic updating of a personalized "digital twin" via Bayesian inference.

4. Operational scaffolding for deployment: a privacy-preserving architecture table separating on-device from server-side components, a safety and regulatory framework with risk-tiered interventions, and an equity and accessibility framework covering algorithmic bias, the digital divide, inclusive design, and governance.

5. A consolidated survey (Table 1) of nine existing personalization approaches for healthcare LFMs, spanning causal discovery on EHR (CausalMed), group-level recommendations (HeLM), finetuned LLMs with wearable data (PH-LLM), prompting GPT-4-turbo with Fitbit data (PhysioLLM), time-series-to-language models (Time2Lang), federated fine-tuning, agent-based simulation (MedAgentSim), language-assisted medication recommendation, and omics/chemical LFM integration (UniCure).

Main Findings

• Personalization and external validity are in tension. Chekroud et al. (2024) trained machine learning models to predict schizophrenia treatment outcomes from trial data. Within-trial performance was strong (AUC > 0.70) but collapsed to chance (AUC ≈ 0.50) when applied to independent trials with identical treatments and similar populations. The paper treats this as a structural limitation rather than a calibration problem.

• Technical privacy fixes are described as insufficient on their own. Differential privacy degrades accuracy, federated learning leaks information through gradients, genomic data is described as inherently identifiable, and behavioral patterns create unique fingerprints. The proposed design requirement is that individual validation occur locally on user devices with minimal data transmission.

• Population-scale training does not automatically transfer to individuals. The paper argues the "average patient" is a mathematical abstraction, and that models trained on millions cannot identify which subgroup an individual belongs to without individual-level evidence.

• Efficiency gains can conflict with human-centered care. Black-box opacity is described as preventing meaningful explanation and undermining shared decision-making, while experimental validation is presented as producing interpretable evidence patients and clinicians can understand together.

• Illustrative chronic migraine case study. A hypothetical patient, Alice, has 12 migraine days per month despite trying multiple preventive medications; clinical trials report response rates of only 40–60%. The LFM produces ranked candidates: magnesium supplement (0.72, σ = 0.30), sleep regularity (0.68, σ = 0.32), propranolol 40 mg (0.65, σ = 0.15), and caffeine reduction (0.61, σ = 0.23). With an uncertainty threshold of τ = 0.25, magnesium and sleep regularity trigger N-of-1 validation while propranolol and caffeine reduction do not.

• The illustrative N-of-1 trial design. Six periods × 2 weeks each, block-randomized, yielding sequences such as (ABC)(BCA) or (BAC)(ABC); primary outcome is migraine days per period self-reported via mobile app; secondary outcomes are pain intensity (0–10 scale), functional disability, and medication use; data collection is a daily headache diary plus wearable-tracked sleep quality. After 12 weeks, the paper reports an example result: a 90% posterior probability that migraine days are reduced by at least 2 days per month, versus 70% for a sleep regularity protocol. These numbers are explicitly labeled as examples ("example numbers," "a result may be").

• Bayesian updating is the formal mechanism. The posterior P(θ_Alice | D_Alice) ∝ P(D_Alice | θ_Alice) · P(θ_Alice | θ_pop), where θ_pop is the LFM's population prior and D_Alice is Alice's trial data.

• Privacy architecture. On-device components handle raw data storage (local encryption, AES-256), trial execution, posterior update, and the digital twin. Server-side components handle LFM inference on feature embeddings (described as reconstruction-resistant), population priors via secure aggregation, prior contribution with clipped gradients plus noise under (ε, δ)-differential privacy, and public trial templates.

• Adaptive trial variants are proposed using Bayesian integration of population priors, contextual bandits to balance exploration and exploitation, and uncertainty-aware adaptation that runs more experiments when confidence is low.

• No empirical evaluation of the proposed framework is reported. The case study is explicitly illustrative.

Methodology in Plain English

The paper is a conceptual and argumentative contribution rather than an empirical study. The authors proceed in four moves.

First, they define conditions under which a population-level model could guarantee optimal personalized recommendations, then show that those conditions rarely hold in practice — Condition 1 is described as satisfied only in scarce situations, and rare diseases by definition lack population data to train on.

Second, they survey nine existing approaches to personalization in healthcare LFMs and categorize how each handles (or ignores) personalization, ranging from explicit causal discovery on longitudinal EHR data to approaches that deliberately ignore personal characteristics in the prompt.

Third, they diagnose four recurring paradoxes by pairing each with empirical evidence, a mechanistic explanation, and a concrete design requirement. The generalizability paradox is illustrated with the schizophrenia outcome prediction result.

Fourth, they construct the hybrid proposal: the LFM acts as a population prior and hypothesis generator; the individual runs a randomized crossover experiment on themselves; results are analyzed with Bayesian updating on-device; and the personalized model adapts. They then work through a hypothetical chronic migraine patient to show the mechanics end to end, and add tables specifying privacy mechanisms, risk-tiered oversight, and equity safeguards.

Why This Matters

Impact on research. The paper reframes personalization as a causal inference problem rather than a modeling capacity problem, and argues that the boundary between prediction and causation must be made explicit for responsible AI integration in personalized medicine. It also provides a named vocabulary (generalizability, privacy-performance, scale-specificity, and automation-empathy paradoxes) for tensions that are otherwise discussed piecemeal.

Real-world applications (as described in the paper):

• Chronic condition self-management such as the chronic migraine scenario, where patients alternate between candidate interventions (magnesium, sleep regularity, propranolol, caffeine reduction) and record outcomes locally.
• Lifestyle and behavioral interventions — the paper's scope explicitly includes lifestyle interventions and any behavior to maintain or improve health, alongside medical treatments.
• Communication and interface personalization for AI systems — comparing prompt-tuned versus retrieval-augmented generation versions, memory-enabled versus memory-free responses, or formal versus casual communication styles across sessions or days, measured by user satisfaction, task success, and engagement.
• Medication dosing decisions such as which medication at which dosage is optimal to control high blood pressure.
• Low-resource and access-constrained settings via paper-based outcome tracking with periodic digitization, community health workers acting as proxies, offline local trial execution with opportunistic sync, and device lending programs.

Industry relevance. The paper speaks directly to developers of clinical decision support and digital health products. It proposes that systems quantify prediction uncertainty and trigger validation when uncertainty thresholds on treatment effect estimates are exceeded; that intended use be specified to distinguish decision support from autonomous recommendation for SaMD classification under FDA/EU MDR scope; that post-market surveillance monitor performance drift and document model updates; and that low-reliability recommendations be flagged for clinician review. It also proposes stratification of interventions into risk tiers, with lifestyle and supplements as low risk and fully N-of-1 eligible, common medications as medium risk requiring clinical oversight and IRB review for systematic deployment, and surgery and chemotherapy as high risk allowing LFM hypothesis generation only, with RCT evidence required and no self-experimentation.

Future Directions

• How to scale N-of-1 trials and make them broadly available to the population. The paper states this question remains open despite the approach's advantages.

• How much causal understanding is actually required for personalized recommendations, as opposed to the mere predictive capacities of LFMs. The paper names this as an open question rather than resolving it.

• Demonstrating efficacy of the hybrid framework against alternative digital twin approaches. The paper notes that existing digital twin frameworks for health interventions may include causal inference and update models with individual-level data, but rely on updating or finetuning without generating individual-level experimental evidence of intervention effectiveness; it states that the efficacy and differences between approaches may stem from the assumptions in Box 1, without reporting a comparison.

• Building the supporting infrastructure the framework depends on: stratified uncertainty monitoring that elevates uncertainty for underrepresented groups and triggers N-of-1 validation more readily, fairness-aware priors to reduce reliance on biased outcome proxies, inclusive trial design feeding summary trial data back into the population LFM, multilingual interfaces with culturally appropriate outcome measures, WCAG 2.1 AA compliance, and clear liability frameworks with open-source components for verification.

Target Audience

Clinician-researchers and biostatisticians working on personalized medicine and N-of-1 trial methodology; AI researchers and engineers building or evaluating foundation models for clinical decision support; health informatics and regulatory professionals concerned with SaMD classification, privacy compliance (HIPAA, GDPR, FDA post-market controls), and post-market surveillance; digital health product teams designing personalization features; and policy or governance audiences focused on algorithmic fairness, the digital divide, and patient agency in AI-mediated care. Readers looking for an empirical benchmark comparison will not find one here — the contribution is conceptual, with an explicitly illustrative case study.

Authors’ abstract

Large foundation models (LFMs) transform healthcare AI in prevention, diagnostics, and treatment. However, whether LFMs can provide truly personalized treatment recommendations remains an open question. Recent research has revealed multiple challenges for personalization, including the fundamental generalizability paradox: models achieving high accuracy in one clinical study perform at chance level in others, demonstrating that personalization and external validity exist in tension. This exemplifies broader contradictions in AI-driven healthcare: the privacy-performance paradox, scale-specificity paradox, and the automation-empathy paradox. As another challenge, the degree of causal understanding required for personalized recommendations, as opposed to mere predictive capacities of LFMs, remains an open question. N-of-1 trials -- crossover self-experiments and the gold standard for individual causal inference in personalized medicine -- resolve these tensions by providing within-person causal evidence while preserving privacy through local experimentation. Despite their impressive capabilities, this paper argues that LFMs cannot replace N-of-1 trials. We argue that LFMs and N-of-1 trials are complementary: LFMs excel at rapid hypothesis generation from population patterns using multimodal data, while N-of-1 trials excel at causal validation for a given individual. We propose a hybrid framework that combines the strengths of both to enable personalization and navigate the identified paradoxes: LFMs generate ranked intervention candidates with uncertainty estimates, which trigger subsequent N-of-1 trials. Clarifying the boundary between prediction and causation and explicitly addressing the paradoxical tensions are essential for responsible AI integration in personalized medicine.